Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5

Adaptive Biotechnologies

Adaptive Biotechnologies

ADPT

0.00

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ: ADPT) with a Overweight and raises the price target from $20 to $27.5.